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Is it a Maze or Math?Masafumi Kitakaze, MD, PHDP ersonalized medicine will be integral in furtherdriving down the global impact of cardiovascu-lar disease. Basic and clinical research in car-
diovascular medicine has rapidly progressed over the
last several decades, causing decreases in mortality
and morbidity. Longevity is a positive consequence
of the battle against the cardiovascular diseases, but
the burgeoning, aging population in the forthcoming
era may shoulder some unintended consequences. In
all developed countries, both aging and an increase
in metabolic syndrome will cause serious concerns,
because the cardiovascular diseases directly related
to these conditions will result in major adverse out-
comes. Therefore, we must ﬁnd novel approaches
to prevent and treat cardiovascular diseases. Most
importantly, we need to learn how to deliver the
beneﬁcial outcomes discovered in basic and clinical
science to daily medical practice for each, unique pa-
tient with cardiovascular disease, which is commonly
known as personalized medicine. In my opinion,
reﬁning personalized medicine to the point that it
can prevent disease or predict outcomes will require
the mathematization of cardiovascular medicine.
First, consider the structure of cardiovascular sci-
ence or medicine. When we assess the spectrum of
cardiovascular diseases, we believe that each cardi-
ologist must apply a 3-dimensional philosophy to
decrease the risks of either mortality or morbidity for
each patient. As an analogy, the x-, y-, and z-axes can
be compared to 3 methods upon which cardiologists
may focus their research efforts: 1) types of research;ovascular Medicine, National Cerebral and
apan.2) methods of data collection; and 3) mathematization
of cardiovascular medical practice.
As for the x-axis, or types of research, our studies
are always classiﬁed as 1 of the following: 1) epidemi-
ological cohort studies; 2) clinical studies, including
observational and randomized studies; 3) trans-
lational studies to link the results of basic studies
to varied clinical arenas; 4) physiological studies
including human, as well as large and small animals;
5) molecular or biological studies; and 6) genetic
studies. All types of research are very important for
best practices in cardiovascular medicine, and papers
in JACC often focus on study types 1 to 3, supported
by the results of study types 4 to 6. However, we, as
researchers, should not be conﬁned to any single type
of study. With a nimble approach, we should evolve
with the demands of the ﬁeld to generate the best
answers for the most difﬁcult questions of how to
improve cardiovascular outcomes for each patient.
This ﬂexibility of an investigator to move from basic
to clinical research is truly necessary to deﬁne novel
management strategies for cardiovascular diseases.
Within each type of research, the method of data
collection, or the y-axis, plays a tremendously
important role. Data acquisition of genes, basic
research, or clinical data can alter the quality and
quantity of clinical medicine or research. To enhance
our quality, data-mining methods, typically used in
the realms of business or economics, can be applied to
cardiovascular research to discover novel manage-
ment strategies or to assess the true efﬁcacy of clin-
ical medicine (1,2).
Finally, we come to the z-axis, which I believe to be
the most important, because all of clinical medicine
should be able to be mathematically expressed.
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science, not to the summation of experiences or sta-
tistics, and natural science should be mathematically
expressed. However, the relationship between each
factor of clinical medicine and clinical outcome is
qualitative, not quantitative, and each essential fac-
tor cannot accurately depict or predict the outcomes
of each unique patient. For example, the patients
with plasma brain natriuretic peptide levels <170
pg/ml showed a 3.4 times higher survival rate during
2.2 years compared with patients with BNP levels
$170 pg/ml in patients with chronic heart failure (3).
This type of analysis only provides the average ten-
dency of survival for the average patient, but we are
obliged to apply this type of knowledge in clinical
practice. The use of statistically proven evidence for
each patient is a characteristic unique to clinical
medicine, because the results and outcomes of basic
science in medicine are both qualitatively and quan-
titatively reproducible. Furthermore, when we eval-
uate the other basic science ﬁelds, such as physics,
chemistry, or its applied sciences of technology
including material mechanics, thermodynamics, or
ﬂuid dynamics, both basic and applied sciences are
sufﬁciently quantitative. Importantly, the observa-
tional phenomena in basic or applied science can be
depicted by a mathematical equation, such as the law
of universal gravitation.
The time it took for an apple to fall from a tree to
the ground was assumed to be dependent on the
gravity, weight, color, or shape of the apple, as well as
the initial speed of the apple. However, Newton
found that only 2 factors—gravity and the initial
speed of the apple—exclusively determined the time
it would take for the apple to reach the ground.
Because clinical medicine and practice are classiﬁed
as natural science, all phenomena, such as the
severity of heart failure and patient characteristics
before the occurrence of clinical events, may provide
the qualitative equation for a clinical outcome.
Therefore, I believe that all of clinical medicine or
practice can be mathematically expressed. Because
the mathematics of a cause-and-effect relationship
predict accurate clinical outcomes, we can correct for
risk factors of patients before the clinical events
might occur. One may claim that there is a disparate
personal response to therapy, because humans are
not machines. However, this may not be a relevant
argument, because if single nucleotide polymorphism
or genetic differences impact clinical outcomes, we
should consider the action of the drugs or the
response to the diseases mathematically normalized
by single nucleotide polymorphism or genetic differ-
ence. The constitution of a mathematical model orequation is critically important, because this may
contribute to personalized medicine and determine
whether our clinical medicine is classiﬁed in natural
science or not (4).
Our group has investigated the possibility of
deriving a mathematical formula for the estimation of
prognosis of the patients with heart failure. For this
purpose, we formulated the equation s ¼ f(x1,., xp),
where x1,.,xp are clinical features and s represents
the clinical outcome for heart failure, and we
attempted to determine the function (f) to mathe-
matically formulate the relationship between the
clinical features and outcomes for these patients. The
mathematical analysis was performed through a
probabilistic modeling of the relational data by
assuming a Poisson process for rehospitalization due
to heart failure and by linearly approximating the
relationship between the clinical factors and the
mean elapsed time to rehospitalization. We collected
and analyzed 402 clinical parameters and identiﬁed
252 factors that substantially inﬂuenced the elapsed
time until rehospitalization. With the probability
model based on the Poisson process, we found that
the actual times to rehospitalization tightly correlated
to estimated elapsed times to rehospitalization.
Therefore, we seemed to establish a mathematical
formula that closely predicted the clinical outcomes
of patients who were hospitalized with heart failure
and discharged after appropriate treatment.
This investigation is only 1 example of the mathe-
matization of medicine. However, we believe it is
fascinating not only because we can predict outcomes
using clinical parameters beforehand, but also
because we can optimize various treatments to ex-
tend the days to hospitalization in patients with heart
failure. The biggest reason for the importance of this
mathematization is the emerging need to personalize
medicine for every patient.
It is difﬁcult to prove that a particular mathe-
matical formula is correct, as no ﬁnalized answer is
ever obtainable in medical science. To help over-
come this problem, we are collecting prospective
data on patients with heart failure in an effort to
predict clinical outcomes. If this equation is proved
correct, the application of these risk factors to indi-
vidual cardiovascular patients may allow us to
distinguish patients who are at low risk from those
who are at high risk, and the patients may beneﬁt
from closer monitoring and aggressive treatment.
Furthermore, if this process were successful, we
could adopt personalized medicine for each cardio-
vascular patient.
This equation example demonstrates that clinical
medicine or practice is a part of natural science,
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thought to be extracted mainly from medical knowl-
edge and the experience of the physicians.
The question is how JACC contributes to these
movements. First, researchers need to forge ahead
with sophisticated translational or clinical in-
vestigations. This type of dedication to the research
process remains important to patch together our
fragments of knowledge with regard to cardiovascu-
lar diseases for a complete understanding of car-
diovascular medicine for each patient. In addition,
an expert will contextualize how these data in
JACC papers ﬁt into the clinical or translational
sciences of cardiovascular medicine through an
editorial comment and the perspectives section
of each original investigation. Second, JACC will
continue to take a global approach, publishing re-
search from varied regions with less or more preva-
lence of cardiovascular disease to shed light on
how to help people with cardiovascular diseases
worldwide.In addition to publishing investigations from the
individual researchers, the Journal will seek to
extend its own philosophy about clinical medicine
and science to decrease the mortality or morbidity
of cardiovascular diseases. The philosophies of x-,
y-, and z-axes allow us to start to break through cur-
rent unresolved issues in cardiovascular medicine.
Finally, as for the most important z-axis, to consider
clinical situations or individual presentations of
certain patients through a mathematical lens will be
extremely critical to maximize the goal of personal-
ized medicine. To achieve the true rewards of our
efforts with x and y, z will be necessary. These paths
lead to better care for patients with cardiovascular
disease. Now, let’s do it.
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